Recent Peer-Reviewed Study Showcases NOVOS Core's Impact on Cardiovascular Health in Adults

NOVOS Core Demonstrates Improvements in Cardiovascular Health

A recent study published in the European Heart Journal Open has underscored the importance of NOVOS Core, a supplement designed to support healthy aging. Conducted at the University of Surrey, this randomized, double-blind placebo-controlled trial, known as the STAMINA trial, found significant enhancements in vascular health among healthy adults aged 40 and above after six months of daily supplementation.

Significance of the Study

The realm of longevity-focused health and wellness has expanded rapidly, yet products often outpace supporting scientific evidence. NOVOS, a biotechnology company dedicated to interventions for healthy aging, has taken a substantial step in addressing this gap. Under the leadership of Professor Christian Heiss, a notable expert in cardiovascular health, the trial demonstrated that NOVOS Core could significantly improve blood vessel function, arterial elasticity, and systolic blood pressure in participants whose measurements were already within the normal range.

Understanding the implications of aging on health is critical—aging is recognized as the primary risk factor for a multitude of chronic conditions emerging later in life. Researchers suggest that biological aging can be influenced by lifestyle changes, showcasing the potential of supplements like NOVOS Core that aim to support these changes effectively.

What Did the Study Find?

After half a year of daily intake, participants who consumed NOVOS Core showcased impressive improvements in three vital measures of vascular health compared to those on a placebo:

1. Blood Vessel Function: The trial's primary endpoint involved flow-mediated dilation (FMD), which gauges how well arteries expand when blood flow increases. Notably, the NOVOS Core group experienced an FMD increase of 47% from the start, equating to an adjusted improvement of 2.9 percentage points compared to the placebo—a change deemed clinically significant according to vascular research.

2. Arterial Flexibility: Measured by carotid-femoral pulse wave velocity (PWV), a key indicator of arterial stiffness and vascular aging, the NOVOS Core group exhibited a decrease in PWV, while those on placebo showed an increase. The difference of 1.18 meters per second between the groups highlights a significant alteration linked to slowed vascular aging, as PWV typically rises with age.

3. Blood Pressure Changes: The study also noted a more substantial decline in systolic blood pressure within the NOVOS Core group, with an adjusted difference of 6.1 mmHg compared to placebo. This is particularly noteworthy as systolic pressure tends to rise as individuals age due to arterial stiffening.

Impressively, blood vessel function began to show positive changes within just one hour of taking the first serving of NOVOS Core, with consistent gains observed throughout the study's duration. Results indicated that participants initially experiencing the lowest vascular function benefited the most from the supplement, while cholesterol levels remained stable, ruling out lipid reduction as a factor.

Rigorous Clinical Standards in Supplement Research

In an industry where clinical trials are rare, NOVOS has elevated the expectations for dietary supplements through rigorous research. The STAMINA trial involved 61 healthy, non-smoking participants aged 40 and up, with 33 on NOVOS Core and 28 on a matching placebo. Exclusions were made for individuals with existing cardiovascular conditions or other serious health concerns. Furthermore, the trial included a higher percentage of women than is typically observed in cardiovascular studies, reflecting a more inclusive approach to research.

Professor Heiss stated, "Our hypothesis was whether a multi-component supplement could positively influence numerous biological processes related to vascular aging. The results indeed suggest it does, marking an encouraging direction for supplements as part of a holistic approach to health."

Future Implications

As the trial focused first on the vascular system, NOVOS is now poised to investigate the effects of NOVOS Core on other aspects of health, including muscle function, cognitive performance, and skin health. The STAMINA trial serves as a vital stepping stone toward a broader understanding of how supporting biological aging can enhance overall well-being.

The full study can be accessed at NOVOS Labs, offering a comprehensive look at the groundbreaking findings. With the commitment to enhance the science of aging, NOVOS aims to redefine expectations for longevity practices in proactive health maintenance.